RA Capital Management 13F holdings, Q3 2020
Holdings as of September 30, 2020 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 70 US equity positions worth $5.5bn in its Q3 2020 13F filing. The largest position was ASND at 16.7% of the reported book, followed by FORMA THERAPEUTICS HLDGS INC and CHEMOCENTRYX INC. Against the Q2 2020 filing, it opened 13 new positions, added to 6 and reduced 10 among the top 50 holdings.
What did RA Capital Management own in Q3 2020? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2020 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 16.7% | $912.0m | 5,909,742 | 20% | added |
| 2 | FORMA THERAPEUTICS HLDGS INC | 8.2% | $449.1m | 9,011,651 | 0% | held | |
| 3 | CHEMOCENTRYX INC | 4.8% | $264.5m | 4,826,910 | 0% | held | |
| 4 | PCVX VAXCYTE INC | Healthcare | 4.8% | $260.9m | 5,283,818 | -4% | reduced |
| 5 | TGTX TG THERAPEUTICS INC | Healthcare | 4.3% | $236.2m | 8,825,849 | -31% | reduced |
| 6 | NKTX NKARTA INC | Healthcare | 3.1% | $168.5m | 5,605,129 | – | new |
| 7 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 2.7% | $145.0m | 2,035,132 | 0% | held |
| 8 | PHAT PHATHOM PHARMACEUTICALS INC | 2.6% | $140.3m | 3,825,008 | 0% | held | |
| 9 | MCRB SERES THERAPEUTICS INC | Healthcare | 2.5% | $134.5m | 4,750,000 | – | new |
| 10 | NVAX NOVAVAX INC | Healthcare | 2.4% | $129.9m | 1,198,602 | -75% | reduced |
| 11 | 89BIO INC | 2.2% | $121.5m | 4,736,214 | 50% | added | |
| 12 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.0% | $111.4m | 5,140,408 | -1% | reduced |
| 13 | MGNX MACROGENICS INC | Healthcare | 2.0% | $110.2m | 4,375,217 | -5% | reduced |
| 14 | EIDOS THERAPEUTICS INC | 2.0% | $109.3m | 2,163,271 | 0% | held | |
| 15 | ITEOS THERAPEUTICS INC | 2.0% | $109.0m | 4,417,258 | – | new | |
| 16 | ZOGENIX INC | 1.8% | $98.4m | 5,488,424 | 49% | added | |
| 17 | ADVERUM BIOTECHNOLOGIES INC | 1.8% | $96.9m | 9,410,860 | 21% | added | |
| 18 | ADAPY ADAPTIMMUNE THERAPEUTICS PLC | Healthcare | 1.7% | $90.4m | 11,329,581 | -13% | reduced |
| 19 | TRILLIUM THERAPEUTICS INC | 1.6% | $87.6m | 6,162,694 | 0% | held | |
| 20 | ARVN ARVINAS INC | Healthcare | 1.6% | $86.7m | 3,672,872 | 0% | held |
| 21 | RETROPHIN INC | 1.6% | $85.6m | 4,635,687 | 0% | held | |
| 22 | KALA PHARMACEUTICALS INC | 1.5% | $81.6m | 10,874,613 | 0% | held | |
| 23 | BLACK DIAMOND THERAPEUTICS INC | 1.4% | $78.3m | 2,589,904 | 0% | held | |
| 24 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.4% | $74.3m | 2,408,292 | -3% | reduced |
| 25 | IGM BIOSCIENCES INC | 1.3% | $72.5m | 982,723 | 0% | held | |
| 26 | KROS KEROS THERAPEUTICS INC | Healthcare | 1.3% | $72.3m | 1,875,000 | 0% | held |
| 27 | VXRT VAXART INC | 1.3% | $71.9m | 10,810,937 | – | new | |
| 28 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.2% | $66.0m | 7,775,207 | 0% | held |
| 29 | PMVP PMV PHARMACEUTICALS INC | 1.1% | $60.7m | 1,710,265 | – | new | |
| 30 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.0% | $56.6m | 2,805,045 | – | new |
| 31 | INOZYME PHARMA INC | 1.0% | $52.7m | 2,003,653 | – | new | |
| 32 | GERN GERON CORP | Healthcare | 1.0% | $52.4m | 30,126,299 | 0% | held |
| 33 | AKOUOS INC | 1.0% | $52.2m | 2,281,249 | 0% | held | |
| 34 | ORCHARD THERAPEUTICS PLC | 0.9% | $50.6m | 12,315,213 | 18% | added | |
| 35 | CRDF CARDIFF ONCOLOGY INC | 0.9% | $46.7m | 3,290,000 | – | new | |
| 36 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.8% | $42.6m | 1,000,000 | – | new |
| 37 | INHIBRX INC | 0.7% | $38.3m | 2,129,003 | – | new | |
| 38 | ALEC ALECTOR INC | Healthcare | 0.7% | $38.1m | 3,618,748 | -12% | reduced |
| 39 | CRINETICS PHARMACEUTICALS INC | 0.7% | $36.5m | 2,328,698 | 0% | held | |
| 40 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.6% | $34.1m | 1,165,184 | 0% | held |
| 41 | ARDX ARDELYX INC | Healthcare | 0.6% | $32.9m | 6,260,904 | 0% | held |
| 42 | VRNA VERONA PHARMA PLC | 0.6% | $31.8m | 5,100,000 | – | new | |
| 43 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.5% | $29.4m | 781,290 | -8% | reduced |
| 44 | SCPHARMACEUTICALS INC | 0.5% | $26.2m | 3,518,998 | 0% | held | |
| 45 | IMMUNOGEN INC | 0.5% | $25.3m | 7,040,485 | – | new | |
| 46 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 0.4% | $23.0m | 1,515,151 | 0% | held |
| 47 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.4% | $21.3m | 2,118,212 | 10% | added |
| 48 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 0.4% | $20.8m | 2,727,272 | 0% | held |
| 49 | PANDION THERAPEUTICS INC | 0.4% | $20.3m | 1,770,023 | – | new | |
| 50 | PREVAIL THERAPEUTICS INC | 0.4% | $19.5m | 1,915,568 | -23% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.